{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:34:34Z","timestamp":1789198474843,"version":"build-2803163510"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Melinta Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,8]]},"DOI":"10.1093\/cid\/ciy1079","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T23:18:01Z","timestamp":1544656681000},"page":"S213-S222","source":"Crossref","is-referenced-by-count":62,"title":["Profile of a Novel Anionic Fluoroquinolone\u2014Delafloxacin"],"prefix":"10.1093","volume":"68","author":[{"given":"Paul M","family":"Tulkens","sequence":"first","affiliation":[{"name":"Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"additional","affiliation":[{"name":"Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H","family":"Zinner","sequence":"additional","affiliation":[{"name":"Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"key\n\t\t\t\t2019040801101663700_CIT0001","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/archinte.168.14.1585","article-title":"National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections","volume":"168","author":"Hersh","year":"2008","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0002","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/cis342","article-title":"Emergency department visit rates for abscess versus other skin infections during the emergence of community-associated methicillin-resistant Staphylococcus aureus, 1997\u20132007","volume":"55","author":"Qualls","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0003","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3201\/eid1509.081228","article-title":"Trends in US hospital admissions for skin and soft tissue infections","volume":"15","author":"Edelsberg","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0004","doi-asserted-by":"crossref","first-page":"e0143276","DOI":"10.1371\/journal.pone.0143276","article-title":"Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact","volume":"10","author":"Kaye","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0005","article-title":"Decreasing incidence of skin and soft tissue infections at 86 U.S. emergency departments, 2009\u20132014","author":"Morgan","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0006","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1093\/clinids\/20.Supplement_2.S279","article-title":"Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use","volume":"20","author":"Summanen","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0007","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.diagmicrobio.2006.05.009","article-title":"Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998\u20132004)","volume":"57","author":"Moet","year":"2007","journal-title":"Diagnostic Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0008","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajic.2010.03.018","article-title":"Outcomes and management costs in patients hospitalized for skin and skin-structure infections","volume":"39","author":"Itani","year":"2011","journal-title":"Am J Infect Control"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0009","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/jac\/dkx200","article-title":"Emerging multidrug resistance in community-associated Staphylococcus aureus involved in skin and soft tissue infections and nasal colonization","volume":"72","author":"Lee","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.annemergmed.2007.12.004","article-title":"Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus","volume":"51","author":"Pallin","year":"2008","journal-title":"Ann Emerg Med"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0011","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2334-14-296","article-title":"Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009","volume":"14","author":"Suaya","year":"2014","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0012","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1093\/jac\/dkg250","article-title":"Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter","volume":"51","author":"Nathwani","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0013","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0014","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1198-743X(16)30095-7","article-title":"Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections","volume":"22","author":"Russo","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0015","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/jac\/dkt129","article-title":"Community-associated Clostridium difficile infection and antibiotics: a meta-analysis","volume":"68","author":"Deshpande","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0016","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.chom.2013.01.001","article-title":"A lesson in survival: S. aureus versus the skin","volume":"13","author":"Alonzo","year":"2013","journal-title":"Cell Host Microbe"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0018","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.chom.2012.11.012","article-title":"Functional modularity of the arginine catabolic mobile element contributes to the success of USA300 methicillin-resistant Staphylococcus aureus","volume":"13","author":"Thurlow","year":"2013","journal-title":"Cell Host Microbe"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0019","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tim.2008.11.005","article-title":"Staphylococcus aureus: new evidence for intracellular persistence","volume":"17","author":"Garzoni","year":"2009","journal-title":"Trends Microbiol"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1524-475X.2007.00321.x","article-title":"Biofilms in chronic wounds","volume":"16","author":"James","year":"2008","journal-title":"Wound Repair Regen"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0021","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/0001555574375379","article-title":"In vivo studies concerning a pH gradient in human stratum corneum and upper epidermis","volume":"74","author":"Ohman","year":"1994","journal-title":"Acta Derm Venereol"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0022","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.03482-14","article-title":"Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates","volume":"58","author":"Siala","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0023","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1073\/pnas.75.7.3327","article-title":"Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents","volume":"75","author":"Ohkuma","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0024","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/17425255.2017.1386654","article-title":"Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections","volume":"13","author":"Bassetti","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0025","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2147\/IDR.S142140","article-title":"Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin","volume":"11","author":"Righi","year":"2018","journal-title":"Infect Drug Resist"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect Dis Ther"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0027","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/phar.2050","article-title":"What is old is new again: delafloxacin, a modern fluoroquinolone","volume":"38","author":"Cho","year":"2018","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0028","unstructured":"Duffy EM , DeVitoJA, RemyJM, BurakES. Delafloxacin chemical properties lead to increased potency against gram-positive pathogens, including quinolone-resistant pathogens (II) (Poster E-183). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, Massachusetts: American Society for Microbiology, 2010."},{"key":"key\n\t\t\t\t2019040801101663700_CIT0029","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0030","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: a novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0031","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0032","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-Gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0033","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Van Bambeke","year":"2015","journal-title":"Future Microbiol"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0034","doi-asserted-by":"crossref","first-page":"e01667","DOI":"10.1128\/mBio.01667-14","article-title":"The extracellular matrix of Staphylococcus aureus biofilms comprises cytoplasmic proteins that associate with the cell surface in response to decreasing pH","volume":"5","author":"Foulston","year":"2014","journal-title":"MBio"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0035","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0036","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/DDDT.S106071","article-title":"Delafloxacin: design, development and potential place in therapy","volume":"11","author":"Candel","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0037","unstructured":"Ohshita Y , YazakiA. In vitro studies with WQ-3034, a newly synthesized acidic fluoroquinolone (abstract F164). In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada, 1997."},{"key":"key\n\t\t\t\t2019040801101663700_CIT0038","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1128\/AAC.48.7.2771-2777.2004","article-title":"In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms","volume":"48","author":"Almer","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0039","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0040","article-title":"Activity of delafloxacin when tested against bacterial surveillance isolates collected in the US and Europe during 2014\u20132016 as part of a global surveillance program (poster 1222)","volume-title":"ID Week 2017","author":"Flamm","year":"2017"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0041","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jac\/dkh304","article-title":"The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae","volume":"54","author":"Hammerschlag","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0042","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.02798-15","article-title":"In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance","volume":"60","author":"Soge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0043","doi-asserted-by":"crossref","first-page":"e00772","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0044","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.juro.2015.01.094","article-title":"Effects of urine matrix and pH on the potency of delafloxacin and ciprofloxacin against urogenic Escherichia coli and Klebsiella pneumoniae","volume":"194","author":"So","year":"2015","journal-title":"J Urol"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0045","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.00181-13","article-title":"A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0046","doi-asserted-by":"crossref","first-page":"13286","DOI":"10.1038\/ncomms13286","article-title":"The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase","volume":"7","author":"Siala","year":"2016","journal-title":"Nat Commun"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0047","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3109\/00498254.2015.1042946","article-title":"Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration","volume":"45","author":"McEwen","year":"2015","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0048","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinthera.2015.10.016","article-title":"Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0049","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","article-title":"Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0050","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jcph.1041","article-title":"Delafloxacin pharmacokinetics in subjects with varying degrees of renal function","volume":"58","author":"Hoover","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0051","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jcph.817","article-title":"Clinical pharmacology of delafloxacin in patients with hepatic impairment","volume":"57","author":"Hoover","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0052","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.clinthera.2017.04.009","article-title":"The pharmacokinetics of the CYP3A substrate midazolam after steady-state dosing of delafloxacin","volume":"39","author":"Paulson","year":"2017","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0053","article-title":"Pharmacokinetic-pharmacodynamic target attainment analyses supporting delafloxacin phase 3 dose regimen decisions (poster A1-681)","author":"Rubino","year":"2010"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0054","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dkh242","article-title":"ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model","volume":"54","author":"Firsov","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijantimicag.2004.02.026","article-title":"Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model","volume":"24","author":"Zinner","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0056","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2005.02.004","article-title":"Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model","volume":"25","author":"Firsov","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0057","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1128\/AAC.00647-16","article-title":"In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model","volume":"60","author":"Lepak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0058","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","article-title":"Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens","volume":"48","author":"Thabit","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0059","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0060","unstructured":"European Medicines Agency (EMA). Public hearing on quinolones and fluoroquinolones: summary of safety concerns and list of questions. Available at: http:\/\/www.ema.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500247105. Accessed December 8, 2018."},{"key":"key\n\t\t\t\t2019040801101663700_CIT0061","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0062","author":"European Medicines Agency (EMA)"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0063","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11634300-000000000-00000","article-title":"Moxifloxacin safety: an analysis of 14 years of clinical data","volume":"12","author":"Tulkens","year":"2012","journal-title":"Drugs R D"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0064","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections","volume":"30","author":"O\u2019Riordan","year":"2015","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0065","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0066","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin","volume":"71","author":"Kingsley","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0067","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0068","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1469-0691.2005.01131.x","article-title":"Quinolones in 2005: an update","volume":"11","author":"Van Bambeke","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019040801101663700_CIT0069","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1039\/C8PP00019K","article-title":"Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin","volume":"17","author":"Dawe","year":"2018","journal-title":"Photochem Photobiol Sci"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/Supplement_3\/S213\/28280468\/ciy1079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T23:02:29Z","timestamp":1694473349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/Supplement_3\/S213\/5428805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":69,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2019,4,8]]},"published-print":{"date-parts":[[2019,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy1079","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,1]]},"published":{"date-parts":[[2019,4,1]]}}}